Ashish Kacholia bought Credent Connect N Care at ₹187 on 23 July 2026, three weeks before the IPO, and is up 82% on paper. FY26 profit rose to ₹18 crore with bought-in businesses, but cash flow was negative
Ashish Kacholia holds 1.47% of Credent Connect N Care, and the IPO prospectus says how he got it: on 23 July 2026 he bought 2,67,600 shares at ₹187 each, about ₹5 crore, from a promoter, three weeks before the IPO. At the ₹340 close on 16 October his shares are worth about ₹9.1 crore, a paper gain of about 82%. The company's FY26 profit rose to ₹18 crore, but that includes businesses it bought in the year, and its cash flow was negative.
Credent Connect N Care (listed on NSE SME, 20 August 2026) - Share price: ₹340.45 (16 October 2026 close; IPO price ₹189) - Market cap: ₹620 crore - P/E: about 34x on trailing profit (Metropolis 53x, Thyrocare 43x; my picks, because the RHP names no peer) - 52-week range: ₹309 to ₹420
The investor claim, and what the prospectus shows
- The claim: Tradebrains (August 2026) said Kacholia appeared in the shareholding pattern with a 1.47% stake, about 2.68 lakh shares. - The record: the RHP (the offer document filed before the IPO) lists a pre-IPO sale on 23 July 2026 at ₹187 a share by promoter Ashok Kumar Sharma to a group of investors. The RHP's cost table lists Kacholia for 2,67,600 shares at ₹187 (₹5.00 crore), and the post-IPO 1.47% matches that count. The RHP labels the table "acquisition by Ashok Kumar Sharma" but shows him as the transferor, so I read it as a sale by him, which is my inference. - Not an anchor and not a market buy: he is not in the anchor list, and I found no bulk deal by him. - His stake: 2.02% before the IPO and 1.47% after it. The RHP says all pre-IPO shares held by non-promoters are locked in for one year from the IPO allotment (18 August 2026), so until about August 2027. - Where he stands: ₹187 compared with ₹189 for the IPO and anchors, so he paid about the same as IPO investors. At ₹340 he has a paper gain of 82%, before tax and costs. The shares opened at ₹359.10 on listing day. - Others in the same sale at ₹187: Abakkus Venture Opportunities Fund (1,60,800 shares, ₹3.0 crore, 1.21% before the IPO), Convivial Advisors LLP (1,42,200 shares) and about 20 smaller buyers. The sale totalled 8,73,600 shares.
What the company does
Credent supplies services to medical labs and hospitals. It sends staff such as blood-sample collectors to patients' homes and to labs. It runs temperature-controlled (2 to 8 °C) transport of samples and reagents. It also sells corporate wellness camps, a courier service (C3 Post) and IT support. It had 2,589 riders and 97 vehicles at 30 June 2026, served 2,530 labs in FY26, and had 6,338 staff at 31 March 2026, of whom 2,286 are contract staff.
It was incorporated in June 2015 in Delhi as Credent Cold Chain Logistics Private Limited, became a public company in October 2025 and changed its name on 28 October 2025. It rents all its offices and warehouses.
Revenue by business, FY26 (₹214 crore):
FY26 revenue of ₹214 crore against ₹78 crore of parent-only revenue in FY25 is not organic growth. Healthcare services were 12% of FY25 parent-only revenue and 43% of FY26. The jump comes mostly from Credent Healthcare, which it bought on 2 April 2025 (that subsidiary alone had ₹72.6 crore of FY26 revenue). It also bought two smaller firms, Credent Team and Alltrak Technologies, in December 2025 and February 2026.
The financials
Restated, ₹ crore, years to March. FY26 is consolidated (the parent plus three subsidiaries bought during the year); FY24 and FY25 are the parent alone, so the growth is not like for like:
FY24 FY25 FY26 ------------ Revenue 75.7 77.9 214.2 Operating profit (EBITDA) 4.3 5.0 28.5 Operating margin 5.7% 6.4% 13.3% Net profit 2.7 2.2 18.4 Net worth 13.7 15.9 43.8 Borrowings 6.8 7.4 21.9
FY26 is the latest full year in the RHP. The company has not yet published results since the listing; half-year results are due by mid-November. The RHP's own figures give a return on net worth of 42% in FY26.
Does profit turn into cash? Not in FY26
₹ crore FY24 FY25 FY26 ------------ Net profit 2.7 2.2 18.4 Cash from operations 0.8 5.5 -6.6
In FY26 profit before changes in working capital was ₹29.3 crore, but receivables grew by ₹28.4 crore, payables fell by ₹3.4 crore and the company paid ₹5.7 crore in tax. Slower collections are the biggest single reason, not the only one. It paid for acquisitions with ₹10.8 crore and funded the gap with ₹19.9 crore of new borrowing.
- Trade receivables (money customers owe): ₹58.8 crore at March 2026, against ₹17.9 crore a year before. About 100 days of sales on the year-end balance (my calculation). The company has set aside no allowance for bad debts against them. That is an accounting choice, not proof that all of it will be collected. ₹46.4 crore of it is under 6 months old, and ₹8.7 crore is billing not yet sent. - Trade payables (money owed to suppliers): only ₹1.0 crore, about 5 days. The company collects slowly but pays almost at once. - Fixed assets: ₹7.3 crore (net block), plus goodwill of ₹2.3 crore and intangibles of ₹2.0 crore. - Employee cost is 39.5% of revenue (₹84.6 crore). - Borrowings: ₹21.9 crore at March 2026, mostly short-term, and ₹23.0 crore at 30 June 2026. The promoters gave personal guarantees on a large part.
How the IPO went
- Dates: 13 to 17 August 2026. Price band ₹179 to ₹189, final price ₹189. Listed on NSE SME on 20 August at about ₹359 (opened at ₹359.10, about 90% above the issue price). Subscribed about 107 times per Chittorgarh; other sites report 142 to 153 times. I could not tell whether the gap is a different basis or a later update. - Size: about ₹93.9 crore, all new shares (49.68 lakh). - Anchors (₹26.54 crore, 12 August 2026, 10 anchors): Abakkus Venture Opportunities Fund ₹5 crore and Mint Focussed Growth Fund (an Abakkus-linked fund) ₹5 crore, Hem Growth Opportunities Fund ₹4.48 crore, Motilal Oswal Finvest ₹4 crore, 360 ONE ₹1 crore and five more. The second half of the anchor lock-in ends on about 16 November 2026 (sources differ by a day). - Where the money goes: about ₹64 crore for working capital (₹37 crore for the company, plus ₹26.8 crore put into a subsidiary for its working capital), ₹6 crore to repay borrowings, ₹3 crore for machinery in the subsidiary, about ₹8.9 crore for general use and about ₹12.2 crore of issue costs. - After listing, buyers on the first days included Motilal Oswal Financial Services (2.98 lakh shares at ₹374) and Neo Apex Share Broking (1.44 lakh at ₹358). I did not see Kacholia or Abakkus in any bulk deal.
Who runs it
- Tarun Sharma, 39, chairman and managing director, B.Com (Hons), 12 years' experience. - Karan Sharma, 36, whole-time director, MBA. According to the exchange announcement list, he resigned as chief financial officer on 18 September 2026 and Sachin Sharma was appointed CFO. He stays on the board. - Ashok Kumar Sharma, 67, non-executive director and the seller in the pre-IPO deal. He was on the registrar's list of disqualified directors from November 2016 to October 2021, after a Credent company failed to file returns for three years. - Promoters held 87.52% before the IPO and about 63.7% after. The family also includes Dimple Sharma and Tanveen Sharma. - Related-party dealings: promoters have lent the company money (₹1.25 crore from Dimple Sharma and ₹0.99 crore from Ashok Sharma at March 2026). Alltrak Technologies was a customer, paying ₹14.2 crore of FY24 revenue before it became a subsidiary, and owes the company a loan of ₹2.9 crore.
Customers
The top 10 customers were 81.8% of FY26 revenue (83.3% in FY25), and the top 5 were 59.1%. The biggest was 15.8%. The RHP does not name them, and there are no fixed contracts with the top 10. In FY24 the biggest customer, at 18.7%, appears to be Alltrak, which the company later bought. That is my reading of identical figures.
Is it expensive?
The RHP says there are no listed companies doing similar work, so it lists no peers. On FY26 profit per share of ₹13.95, the ₹189 issue price was 13.5 times earnings. At ₹340 the market cap of ₹620 crore is about 34 times trailing profit on the data site's basis, as of the 16 October close (the data site and Chittorgarh use different market caps; I could not reconcile them). All three P/E figures come from the same data site on the same date.
My own reference points: Metropolis Healthcare at 52.9x and Thyrocare at 42.7x on trailing profit. They are diagnostic labs, which are Credent's customers, not direct peers.
What management says (its own forward-looking statements)
I found no earnings call, investor presentation or filed guidance. A minor website's summary of an investor deck mentions a long-term growth aim, but I could not verify it from a company filing, so I do not repeat the number. The RHP says the company has not yet placed orders for the machinery it plans to buy with the issue money. There is no earlier guidance to compare, because the company listed only in August 2026.
Risks
- Cash. Cash from operations was negative in FY26, and receivables are about 100 days of sales. - Customers. Ten customers bring 82% of revenue, with no fixed contracts. - Bought-in growth. Most of the FY26 jump comes from acquired firms. Alltrak lost money in FY24 and FY25. - People cost. Staff cost is nearly 40% of revenue, and a third of staff are on contract. - Governance. A promoter's earlier disqualification, personal guarantees, loans from promoters, the CFO change on 18 September 2026 and some discrepancies in company-registry filings that the RHP lists. - Working capital. About ₹64 crore, or two-thirds of the IPO money, goes to working capital. - Supply. The second half of the anchor lock-in ends on about 16 November 2026 (sources differ by a day). - SME stock. Few shares trade and prices can swing sharply.
The one thing to remember Kacholia paid ₹187, close to the IPO price, and he is up 82% on paper because the stock rose about 80% after the IPO. A buyer today pays ₹340 for a business whose cash flow has not caught up with its profit.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.com/content/ipo/RHPCREDENT.zip - https://nsearchives.nseindia.com/corporate/CREDENT05092026222313AnnualReportC3Final.pdf - https://www.chittorgarh.com/ipo/credent-connect-ipo-ipo/2991/ - https://www.digitalhealthnews.com/credent-connect-n-care-raises-inr-26-5-cr-from-anchor-investors-ahead-of-ipo - https://www.tradingview.com/news/moodys:58289f29eafa2:0-ashish-kacholia-owned-credent-connect-n-care-ipo-opens-today-gmp-subscription-status-other-details-in-10-points/ - https://tradebrains.in/indian-markets/healthcare-stock-in-focus-as-ashish-kacholia-appears-in-shareholding-pattern-with-147-stake-12459283 - https://www.arthneeti.com/insights/credent-connect-n-care-q1-fy27-earnings